Glitazone use associated with reduced risk of Parkinson's disease.

ABSTRACT:

Background

Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease-preventing effect may be plausible. The objective of this study was to examine if the use of glitazone drugs is associated with a lower incidence of PD among diabetic patients.

Methods

We compared the incidence of PD between individuals with diabetes who used glitazones, with or without metformin, and individuals using only metformin in the Norwegian Prescription Database. This database contains all prescription drugs dispensed for the entire Norwegian population. We identified 94,349 metformin users and 8396 glitazone users during a 10-year period and

SUBMITTER: Brakedal B 

PROVIDER: S-EPMC5697685 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature